Latest news with #BLI
Time of India
11 hours ago
- Health
- Time of India
Are antibiotics losing battle against typhoid?
1 2 3 Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India. Ahmedabad: A recent study has raised alarm bells about the growing resistance of typhoid-causing bacteria to several antibiotics, in some cases up to 90%, potentially complicating treatment options for this common disease. This study by Gujarat Biotechnology Research Centre (GBRC) scientists, along with other organisations, is the latest among several studies in the past decade that flagged the rise of AMR typhoid in Gujarat and in India. Researchers studied isolated Salmonella Typhi or S Typhi, the bacteria responsible for typhoid fever, collected from Ahmedabad and Vadodara against 28 antibiotics used for treatment of typhoid and found several of them showing over 90% resistance. The group also pinpointed genes for third-generation antibiotics for some classes and suggested another class of antibiotics. Typhoid fever, caused by contaminated food or water or poor hygiene, is a common disease for Asia, Africa and Latin America and is marked by fever, fatigue, abdominal pain, rashes and in extreme cases, intestinal bleeding. Symptoms generally last for five to six days and doctors generally use antibiotics for treatment. In Ahmedabad city, monsoons often see 200-odd cases a month. The study, 'Comprehensive analysis of extensive drug-resistant Salmonella Typhi in Gujarat region, India: genomic findings and prospective alternative therapy' was recently published in the American Society for Microbiology journal Microbiology Spectrum. Its authors include SD Akshay, Heli Upadhyaya and 16 others from GBRC, MS University of Baroda, BJ Medical College, state govt's Commissionerate of Health, and Toprani Labs in Vadodara. 'Determining fluoroquinolones (FQs) and third-generation cephalosporin resistance underscores the urgent need for alternative therapeutic strategiesOur research revealed alarming resistance trends to key antibiotics, such as ceftriaxone, cotrimoxazole, amikacin, ampicillin, cefepime, cefixime, cefotaxime, ciprofloxacin, tetracycline, and gentamicin, limiting effective hospital treatment approaches,' the findings state. The researchers also highlighted the role of specific plasmids that carry resistance genes.'Our findings revealed that combination therapy with β-lactam antibiotics and β-lactam inhibitors (BLI) significantly improved the treatment efficacy against extensively drug resistant (XDR) S. Typhi, contributing to more favourable clinical results and reducing treatment failures,' read the findings, adding that this can effectively manage infections and avoid resistance development. Health experts in Ahmedabad say that the drug-resistant typhoid has been a reality for nearly a decade, in varied frequencies. Dr Urvesh Shah, professor and head of GCS Medical College's microbiology department, said that quinolone, the drug of choice a decade ago, is now getting resistant in more than 50% cases. "While third-generation cephalosporin are a drug of choice, we now get scattered cases of its resistance, which is alarming. While azithromycin retains its sensitivity, it should be given as a supplementary drug only," said Dr Shah, adding that the bottom line from such findings is steady rise of drug-resistant bacteria which should be addressed through proper use of drugs, their proper duration, and correct diagnosis. Dr RC Damani, internal medicine specialist at KD Hospital, said that compared to the scenario a decade ago, the medical fraternity is now forced to look at alternatives for the AMR typhoid. "Treatment protocols have changed today for antibiotic use. There is better screening also for determining typhoid cases," he said, adding that not all cases of typhoid are of AMR organisms. "The two popular methods to confirm typhoid are blood culture to determine bacteria and sonography to find signs such as swollen lymph nodes. While some start treatment for symptoms, the wrong use of antibiotics can add to the burden of AMR. Typhoid is a very common disease and we have seen a change in form of its duration from five days to seven days and treatment from oral medication to IV in serious cases," said Dr Pragnesh Vachcharajani, secretary of the Federation of Family Physicians' Association of India.
Business Wire
22-04-2025
- Business
- Business Wire
Antibody Solutions Launches Single Plasma B-Cell Services through Cellestive Discovery Platform
SANTA CLARA, Calif.--(BUSINESS WIRE)--Antibody Solutions, a leading provider of fit-for-purpose antibody discovery services, announced today that for the first time, single plasma B-cell discovery services will be part of the company's exclusive Cellestive antibody discovery platform. The new capability completes a trifecta of B-cell services offered through Cellestive, which already includes discovery pathways for both activated and memory B-cells. The new plasma B-cell service is projected to be of particular value to clients pursuing difficult targets in antibody discovery, enabling them to leverage new processes and technologies while accessing broader, deeper data to inform their decision-making. 'This really rounds out our Cellestive platform and allows us to robustly and efficiently interrogate single plasma B-cells for our clients,' said John Kenney, Phd, co-founder and president of Antibody Solutions. 'Now, we can capture the entire antigen-specific B-cell repertoire from an immune host by using the hybridoma, memory B-cell, and new plasma B-cell discovery pathways, and get vetted sequences from those pathways. There's incredible value in being able to combine sequence-based and function-based screening from essentially any cell that's secreting an antibody.' The new service will leverage a proprietary technology that has the capacity to interrogate, in a single run, more plasma B-cells than current competing technologies. During a run, it can screen antibodies against both soluble antigens and target cells simultaneously, and its AI-driven screening software can rank hits, define multiple unique phenotypes, and prioritize clones for recovery. In addition, fast set-up and processing times allow for greater than 1 million assays to be run in a single workday, making it ideal for difficult targets that demand maximum throughput with a broad range of parameters. Antibody Solutions' clients can begin using plasma B-cell discovery services immediately. Included in each project will be the optimization of analysis conditions, a high-throughput multiparameter screen, recovery of paired heavy and light chain sequences and analysis, high-throughput re-expression, and subsequent analysis including ELISA, Flow Cytometry, and BLI for the validation of antibody binding to the target(s) of interest. 'We're confident that our antibody discovery platform can deliver high-quality inputs that will be perfectly tailored to generate the best outputs,' said Kenney. 'We can now exploit all populations of antigen-stimulated B-cells to discover novel antibody therapeutics. We're excited to bring Cellestive to a new level and offer truly comprehensive solutions to our clients' antibody discovery needs.' About Antibody Solutions Antibody Solutions empowers companies to advance their discovery by delivering fit-for-purpose antibodies. Their Cellestive platform provides comprehensive discovery services with a fee-for-service, pay-as-you-go business model. With a long-standing reputation and a time-tested discovery process, Antibody Solutions has served more than 800 clients since 1995. Headquartered in Santa Clara, CA they serve clients worldwide.
